Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older

NCT01162122 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01162122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01162122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2010
Completion date
November 30, 2011
Enrollment
7,109 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

influenza